Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (421-430 of 497) with videos related to

Pageof 50
Sort By:
European Heart Journal|February 6, 2013
Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyFreek W A Verheugt, Peter Clemmensen, Roxana Mehran, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Archiv Der Pharmazie|June 25, 2003
Synthesis and cytotoxicity of substituted ethyl 2-phenacyl-3-phenylpyrrole-4-carboxylatesMichael A Evans, Daniel C Smith, Justin M Holub, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
European Journal of Preventive Cardiology|August 31, 2021
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trialsSonia S Anand, Will Hiatt, Leanne Dyal, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50

Showing results (421-430 of 497) with videos related to

Sort By:
Pageof 50
European Heart Journal|February 6, 2013
Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyFreek W A Verheugt, Peter Clemmensen, Roxana Mehran, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Archiv Der Pharmazie|June 25, 2003
Synthesis and cytotoxicity of substituted ethyl 2-phenacyl-3-phenylpyrrole-4-carboxylatesMichael A Evans, Daniel C Smith, Justin M Holub, et al.
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
European Journal of Preventive Cardiology|August 31, 2021
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trialsSonia S Anand, Will Hiatt, Leanne Dyal, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50